MedTrace Logo

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

NCT06705725 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-11-26

No results posted yet for this study

Summary

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Conditions

Interventions

DRUG

CBG002 CAR-T Cell Suspension

Single dose of CAR+ T cells will be infused, and classic "3+3" dose escalation will be applied.

Sponsors & Collaborators

  • Carbiogene Therapeutics Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jie Jin · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-26
Primary Completion
2027-10-25
Completion
2028-02-22

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06705725 on ClinicalTrials.gov